Live Breaking News & Updates on Update Guidelines

Stay updated with breaking news from Update guidelines. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Clinical Overview: Fecal Microbiota Transplantation vs Live Biotherapeutic Products for Management of Recurrent C Difficile Infection

Although antibiotics are the standard-of-care treatment for Clostridioides difficile infection, they can cause further microbiota changes that predispose patients to recurrence. ....

United States , Glenns Tillotson , Anne Gonzales Luna , Torres Soto , American College Of Gastroenterology , Infectious Diseases Society Of America , Ferring Pharmaceuticals Inc , Forum Infect Dis , Department Of Pharmacy Practice , Society For Healthcare Epidemiology Of America , Translational Research , University Of Houston College Pharmacy , Fecal Microbiota Transplantation National Registry , Infectious Diseases Society , American College , Pharmacy Practice , Houston College , Practice Guideline , Healthcare Epidemiology , Update Guidelines , Clin Infect , Practice Guidelines , Microbiota Transplantation National Registry , Bacteremia Transmitted , Fecal Microbiota , Safety Alert ,

Treatment of Clostridioides difficile Infection

This JAMA Patient Page summarizes the American College of Gastroenterology’s 2021 guidelines on treatment of Clostridioides difficile infection. ....

United States , Sahil Khanna , Developer American College Of Gastroenterology , Practice Parameters Committee Table , Division Of Gastroenterology , Society For Healthcare Epidemiology Of America , Infectious Diseases Society Of America , Box Section Ref , American College , Clinical Problem , Guideline Source , Parameters Committee , Future Study , Ongoing Research , Practice Guideline , Infectious Diseases Society , Healthcare Epidemiology , Update Guidelines , Mayo Clinic , Interest Disclosures ,

Tillotts Pharma AG announces that DIFICLIRTM (fidaxomicin) is recommended for the treatment of Clostridioides difficile infection (CDI) by ESCMID

DIFICLIRTM (fidaxomicin) is now recommended as first-line CDI treatment in both European and U.S. guidelines1,2 Significantly fewer patients in the fidaxomicin group than the vancomycin group ....

United States , United Kingdom , Mark Wilcox , Kostenloser Wertpapierhandel , Van Prehn , Susi Teichmann , Tillotts Pharma , Adrian Hill , Antimicrob Chemother , Japanese Zeria Group , Clinical Study Group , Society For Healthcare Epidemiology Of America , Infectious Disease Society Of America , Leeds Teaching Hospitals University Of , Head Of International Operations , Corporate Communications , European Society Of Clinical Microbiology , European Centre For Disease Prevention , First Section Of Tokyo Stock Exchange , Infectious Diseases Society Of America , Zeria Pharmaceutical Co Ltd , European Society , Clinical Microbiology , Infectious Diseases , Infectious Disease Society , International Operations ,